RPC(SZ:000650) Sou Hu Cai Jing·2025-09-16 09:15Market Overview - The overall market showed a mixed performance with the traditional Chinese medicine (TCM) sector experiencing a three-day decline. The leading TCM ETF (560080) closed down 0.18%, with a trading volume exceeding 160 million yuan, a significant increase of 74% compared to the previous period. The ETF has seen a net inflow for 11 consecutive days, totaling 235 million yuan, with its latest scale surpassing 2.4 billion yuan, marking a new high since its listing [1][4]. Stock Performance - The TCM ETF's constituent stocks exhibited varied performance: Renhe Pharmaceutical rose over 5%, while other stocks like Panlong Pharmaceutical and Yiling Pharmaceutical saw slight increases. Conversely, stocks such as Baiyun Mountain and Yunnan Baiyao experienced minor declines [3][6]. Financing and Investment Trends - Leveraged funds are increasingly utilizing ETFs to invest in the TCM consumer sector, with the latest financing balance for the TCM ETF exceeding 77 million yuan and a financing purchase amount of over 10 million yuan recorded recently [4]. Regulatory Developments - The National Medical Products Administration announced new regulations for TCM production supervision, effective from March 1, 2026. These regulations emphasize comprehensive quality control throughout the entire production process, focusing on the source of TCM materials and encouraging modernization and digital transformation in TCM production [6]. Industry Outlook - Analysts predict that the TCM industry will face performance pressure in the first half of 2025 due to weak sales in pharmacy and hospital channels. However, leading OTC companies are expected to show resilience. The industry is undergoing a transformation period influenced by healthcare reforms, with a focus on diversified channels and strong brand power being crucial for future success [7][8]. Company Innovations - Renhe Pharmaceutical's Ulook smart brain-machine glasses have garnered market attention. The glasses are designed to monitor users' brainwaves and provide feedback on focus, emotions, and eye health through a mobile app, although they have not yet begun commercial sales [5].